March 18, 2024

Major adverse cardiovascular events related to phosphodiesterase 5 inhibitors: analysis of real-life data from Eudra-Vigilance database

CNCosimo De NunzioSapienza University of Rome ANAntonio NacchiaCTO Andrea Alesini MGMaria Chiara GrimaldiOspedale Generale Regionale Francesco Miulli

Key Points

Key points are not available for this paper at this time.

Abstract

Phosphodiesterase 5 inhibitors (PDE5i) are the standard medical treatment for erectile dysfunction. Aim of our study was to evaluate the rate of major adverse cardiovascular events (MACE) reported during PDE5i treatment based on Eudra-Vigilance (EV) reports.

KI fragen

Bookmark

View Full Paper

Cite This Study

Nunzio et al. (Mon,) studied this question.

synapsesocial.com/papers/68e7388db6db6435876b1ac8 https://doi.org/https://doi.org/10.23736/s2724-6051.23.05611-2

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

KI fragen

Bookmark

View Full Paper